ARX logo

Aroa Biosurgery Limited Stock Price

ASX:ARX Community·AU$231.2m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 49 Fair Values set on narratives written by author

ARX Share Price Performance

AU$0.67
0.14 (26.42%)
19.0% undervalued intrinsic discount
AU$0.83
Fair Value
AU$0.67
0.14 (26.42%)
19.3% undervalued intrinsic discount
AU$0.83
Fair Value
Price AU$0.67
AnalystConsensusTarget AU$0.83

ARX Community Narratives

AnalystConsensusTarget·Updated
Fair Value AU$0.83 19.0% undervalued intrinsic discount

CMS Reforms And International Expansion Will Drive US Healthcare Adoption

1users have liked this narrative
0users have commented on this narrative
31users have followed this narrative

Recent ARX News & Updates

User avatar

Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence

Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Apr 07
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge

Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business

Mar 24
Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business

Aroa Biosurgery Limited Key Details

NZ$84.7m

Revenue

NZ$12.1m

Cost of Revenue

NZ$72.6m

Gross Profit

NZ$76.4m

Other Expenses

-NZ$3.8m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Nov 24, 2025
Earnings per share (EPS)
-0.011
Gross Margin
85.73%
Net Profit Margin
-4.50%
Debt/Equity Ratio
0%

Aroa Biosurgery Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with excellent balance sheet.

0 Risks
4 Rewards

About ARX

Founded
2007
Employees
n/a
CEO
Brian Ward
WebsiteView website
aroa.com

Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

New Zealand Market Performance

  • 7 Days: 2.6%
  • 3 Months: 5.5%
  • 1 Year: 6.7%
  • Year to Date: 3.3%
Over the last 7 days, the market has risen 2.6%, driven by gains in every sector, especially the Industrials sector. As for the past 12 months, the market is up 6.7%. Looking forward, earnings are forecast to grow by 22% annually. Market details ›